Magenta therapeutics, inc. (MGTA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Cash flows from operating activities:
Net loss

-76,769

-57,515

-35,491

-9,431

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

10,001

10,703

2,259

662

Depreciation and amortization expense

1,843

875

376

6

Loss on disposal of property and equipment

-

-67

-

-

Net amortization (accretion) of premiums (discounts) on marketable securities

1,009

190

-

-

Non-cash interest expense

-

-

-

163

License fees paid in common and preferred stock

-

-

9,275

318

Consultant fees paid in common stock

-

-

-

157

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

1,363

1,811

895

41

Accounts payable

145

2,500

-1,125

1,006

Accrued expenses and other current liabilities

5,089

2,239

3,342

631

Deferred rent

-4,960

-1,246

-

-

Other assets

-

-

4

-

Net cash used in operating activities

-57,103

-41,886

-22,263

-6,529

Cash flows from investing activities:
Purchases of property and equipment

3,060

7,672

2,199

139

Proceeds from sale of property and equipment

-

12

-

-

Purchases of marketable securities

144,371

84,043

-

-

Maturities of marketable securities

148,963

-

-

-

Net cash provided by (used in) investing activities

1,532

-91,703

-2,199

-139

Cash flows from financing activities:
Proceeds from public offerings, net of underwriting discounts and commissions

60,874

93,000

-

-

Proceeds from issuance of redeemable convertible preferred stock

-

52,300

71,695

4,305

Proceeds from issuance of convertible notes payable

-

-

-

6,500

Payments of public offering costs

598

3,094

-

-

Payments of redeemable convertible preferred stock issuance costs

-

88

213

107

Proceeds from issuance of common and restricted stock

-

-

4

13

Proceeds from exercise of common stock options

2,021

29

-

-

Net cash provided by financing activities

62,297

142,147

71,486

10,711

Net increase (decrease) in cash, cash equivalents and restricted cash

6,726

8,558

47,024

4,043

Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment included in accounts payable and accrued expenses

-

1,538

-

375

Conversion of redeemable convertible preferred stock to common stock

-

144,739

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

88

213

107

Cumulative dividends on Series A redeemable convertible preferred stock

-

-

437

197

Reversal of cumulative dividends on Series A redeemable convertible preferred stock

-

-

634

-

Conversion of notes payable and accrued interest into redeemable convertible preferred stock

-

-

-

7,164

Other receivable from investor for redeemable convertible preferred stock

-

-

-

6,250